Thanks for rephrasing. If tweaked human insulin can be as good as—but not better than—insulin analogs, how does that make a compelling business proposition for the insulin *oligopolists?
*NVO, SNY, and LLY.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”